Marken
Marken is recorded as a service provider in 167 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 167 trials · Latest update first
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder
Sponsor Grin Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema
Sponsor Pharvaris Netherlands B.V.
- Start (EU)
- Latest update
- Estimated end
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in 11 countries: Bulgaria, Croatia, Germany, Greece, Hungary, Japan, Poland, Romania, Slovakia, Spain, and the United States of America.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sponsor Calico Life Sciences LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment - EFC17599 / AQUA
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions.
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 1.5 to 3.5 mg basimglurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy
Sponsor Noema Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults
Sponsor Sanofi-Aventis Recherche & Developpement
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Marken?
The 2026-10-09 snapshot links Marken to 167 distinct CTIS trials. Recorded services include Medicinal product management, Direct to patient, Direct to Patient, Direct to Patient IP delivery, among 93 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Marken?
The most frequently recorded therapeutic areas are Immunology, Metabolic Disorders, Neurology, Endocrinology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Marken conducted?
The linked trials record locations in 25 countries, including Spain, Poland, Germany, Italy, France. These are trial locations, not confirmed office locations or countries where Marken delivered services.
What can this page tell me about Marken's trial experience?
Browse 167 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 5 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 9 recorded name variants under Marken. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- MARKEN Germany GmbH
- Marken
- Marken Germany GmbH
- Marken Italy S.r.l.
- Marken Italy s.r.l.
- Marken LLP
- Marken Limited
- Marken Logistics GmbH
- Marken Time Critical Express GmbH